Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Century Therapeutics ( (IPSC) ) just unveiled an announcement.
On December 9, 2025, Century Therapeutics announced the expansion of its Board of Directors from six to eight members, appointing Dr. Martin Murphy and Dr. Han Lee as new directors. Dr. Murphy, with extensive experience in life science investment and company creation, will serve on the Compensation and Nominating and Corporate Governance Committees, while Dr. Lee, with a strong background in capital formation and corporate development, will join the Audit and Compensation Committees. This strategic move is expected to enhance Century’s efforts to advance its iPSC-derived cell therapy programs, including its lead candidate CNTY-813 for type 1 diabetes, potentially delivering significant value to patients and stakeholders.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.
Century Therapeutics’ overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but ongoing operational losses. The technical analysis indicates a bearish trend, and the valuation reflects the company’s current unprofitability. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Century Therapeutics is a biotechnology company that focuses on developing induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating autoimmune diseases and cancer. The company leverages its iPSC cell foundry and Allo-Evasion™ technology to create off-the-shelf cell therapies, which it believes will expand patient access and improve existing treatment options.
Average Trading Volume: 981,458
Technical Sentiment Signal: Sell
Current Market Cap: $45.94M
For an in-depth examination of IPSC stock, go to TipRanks’ Overview page.